Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the FDA label’s warnings about severe acute hepatitis B exacerbations that may occur after discontinuation of BIKTARVY, including the requirement for close clinical and laboratory follow-up for at least several months after stopping.
Category Scores
Accurate Statements
Post-treatment acute exacerbation of hepatitis B can occur after discontinuation of BIKTARVY in patients with HIV-1 and HBV, and patients should be monitored closely for at least several months after stopping.
Supported by PI Section 5.1 (states severe acute exacerbations of hepatitis B may occur with discontinuation of BIKTARVY and requires close clinical and laboratory follow-up for at least several months after stopping) and reinforced in PI Section 17 (patient counseling).
Unsupported Statements
Contradictions
Important Omissions
The label specifies that patients with HIV-1 should be tested for HBV prior to or when initiating BIKTARVY (Section 2.1) and notes monitoring with both clinical and laboratory follow-up (Section 5.1). The AI claim implies monitoring but does not explicitly mention HBV testing prior to initiation or the 'clinical and laboratory' wording.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claim correctly conveys the label’s key safety warning and monitoring duration after discontinuation; no contradictory or unsafe instructions were introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
To more closely mirror the label, explicitly state 'close clinical and laboratory follow-up' and, if relevant to the context, HBV testing prior to or when initiating therapy.